<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>One hundred and eighty-five patients with <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> have been studied serially while receiving regular maintenance treatment with sulphasalazine (SASP) in a dose of 0.5 g four times daily </plain></SENT>
<SENT sid="1" pm="."><plain>The circulating levels of the drug and its principal metabolites during remission do not influence the liability to relapse </plain></SENT>
<SENT sid="2" pm="."><plain>When relapse does occur, the circulating level of <z:chebi fb="0" ids="132842">sulphapyridine</z:chebi> <z:hpo ids='HP_0002527'>falls</z:hpo> and remains depressed until remission occurs </plain></SENT>
<SENT sid="3" pm="."><plain>This fall during a relapse is most pronounced when the patient suffers from universal <z:hpo ids='HP_0002583'>colitis</z:hpo> and is least marked in cases of distal <z:hpo ids='HP_0002583'>colitis</z:hpo> </plain></SENT>
</text></document>